Sun Pharmaceutical Industries Ltd announced today that it has, along with its subsidiaries, executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol.

Under the settlement agreement, MedImmune interalia grants Sun Pharma a license to certain patents, permitting Sun Pharma to continue marketing the generic version of Ethyol in the United States.

According to a Sun Pharma press release, the settlement resolves the entirety of the litigations between the parties. The terms of the settlement were not disclosed.